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positive samples, being underestimated by Ig/TCR method in
25 cases and by m-BCR/ABL quantiﬁcation in 21 cases. We
found signiﬁcantly more false-negative samples by Ig/TCR ap-
proach (70 samples) compared to BCR/ABL quantiﬁcation (20
samples). Altogether, we tested 219 bone marrow (BM), 130
peripheral blood (PB) and 1 cerebrospinal ﬂuid samples. The PB
samples showed signiﬁcantly worse correlation between the two
methods compared to BM (p0.02). In our hands, the quanti-
ﬁcation of BCR/ABL transcripts appears to be a more reliable
method than the generally accepted Ig/TCR-based MRD mon-
itoring as the number of false-negative samples by BCR/ABL
quantiﬁcation is signiﬁcantly lower. This contention is sup-
ported by outcome of our patients who subsequently underwent
allogeneic SCT. In this group BCR/ABL positivity preceding
allogeneic SCT seems to represent a better predictor of subse-
quent relapse than Ig/TCR approach.
Supported by VZ MZO 00064203.
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Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive treatment for patients (pts) with AML and MDS. However, it
may be associated with signiﬁcant toxicity. New regimens are
continuously explored trying to reduce toxicity while retaining
anti-leukemia effect. Treosulfan is a prodrug of a bifunctional
alkylating cytotoxic agent used in the past for the treatment of
ovarian cancer. In-vitro it mediates cytotoxicity against cell lines of
a variety of hematological malignancies including acute leukemia.
In escalated doses it shows myeloablative as well as immunosup-
pressive properties. Initial studies in SCT showed promising re-
sults with relatively limited extramedullary toxicity. In the current
study we explored a regimen of ﬂudarabine (total dose 150 mg/m2)
and treosulfan (12 gr/m2  3) in pts with AML and MDS not
eligible for standard SCT. The study included 24 pts, 15 male, 9
female. The median age was 55 years (range, 30-69). Nineteen had
AML (8 secondary, 5 to MDS, 1 to myeloﬁbrosis, 1 to breast
cancer, 1 to NHL), 5 had MDS. Two pts had a prior autologous
SCT (1 for NHL and 1 for AML). All pts had chemo-sensitive or
untreated disease at the time of SCT; 11 pts were in CR1, 5 in
CR2/3, 6 previously untreated and 2 in untreated relapse. The
donor was an HLA matched sibling (n11) or matched unrelated
(n13). Twenty-one pts engrafted, one later rejected the graft.
Three pts died prior to engraftment. The median time to ANC
0.5  109/ L and platelet 20  109 / L was 15 days (range, 11-21)
and 16 days (range, 11-50), respectively. With a median follow-up
of 12 months (range, 1-27), 16 pts are alive in CR, one of them in
CR 4 months following treatment for post SCT relapse. Eight pts
died (relapse-2, organ toxicity – 2, sepsis - 2, CNS bleeding - 1,
graft rejection - 1). The cumulative incidence of acute and chronic
GVHD was 20% and 41%, respectively. The estimated 1-year
overall and disease-free survival were 66% (95% CI, 11-43) and
63% (95% CI, 11-42), respectively. The cumulative incidence of
relapse at 1- year after SCT is 11% (95% CI, 3-41) and the
cumulative incidence of non-relapse mortality at 1 year is 26%
(95% CI, 13-52). In conclusion, the combination of ﬂudarabine
and treosulfan is relatively safe, with effective anti-leukemia po-
tential, in pts not eligible for myeloablative conditioning. This
regimen merits further study in larger scale studies.
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Relapse of acute myeloid leukemia (AML) following myeloabla-
tive allogeneic stem cell transplantation portends a dismal prog-
nosis. Therapy aimed at enhancing graft-versus-leukemia (GVL)
effect, e.g., by donor leukocyte infusion, has limited success in
AML, and a second ablative transplant is associated with prohibi-
tive mortality in adults. From April 2001 to March 2006, nine
patients, ranging in age from 21 to 57, with high risk myeloid
malignancy (7 AML and 2 advanced myelodysplasia) and overt
bone marrow relapse less than one year after ablative busulfan/
cyclophosphamide conditioning have been treated with a cytore-
ductive regimen of ﬂudarabine (30 mg/m2/day) and cytarabine
(2g/m2/day) for 5 days (-7 through -3) and G-CSF administration
(5 ug/kg daily starting day -8) with or without idarubicin (8 mg/m2
days -7, -5, and -3) (8 cases) or ﬂudarabine 30 mg/m2 for 3 days
and 200 cGy total body irradiation (1 case). G-CSF mobilized
peripheral blood stem cells from their original HLA-matched
donor (8 siblings, 1 unrelated) were infused. Graft versus host
disease (GVHD) prophylaxis was mycophenolate mofetil for 30
days and cyclosporine with a rapid taper. The mean onset of
relapse after the initial ablative transplant was day 172 (range
106-271). Fludarabine-based therapy was well tolerated with no
treatment related mortality. Full donor chimerism was established
by day 72 (range 26-113) in 6 patients (67%). Five patients died: 2
from relapse without GVHD at day 30 and 301 after RIST
(one patient with complex and one with Ph cytogenetic abnor-
malities), 3 from relapse with evidence of GVHD. Four patients
survive: one has relapsed at 91 days after RIST and is receiving
alternate therapy, while three patients (30%) survive in complete
remission at 100, 635 and 1795 days after salvage RIST. In 5
cases (56%), the duration of complete remission after RIST was
longer than after the initial ablative transplant. We conclude that
ﬂudarabine-based RIST is a safe and effective salvage therapy
offering a chance for increased survival with low morbidity in
patients relapsing after ablative transplant. In addition, RIST ther-
apy has resulted in long-term disease free survival in over 20% of
cases in this study.
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Pts with ﬂudarabine-refractory CLL have a poor prognosis with
conventional therapies with median survival of 12 months. We
previously reported 2-year overall survival of 60% for 64 pts
treated with nonablative HCT from related (n44) or unrelated
(n20) donors (Sorror et al. JCO 2005, 23: 3819). Here, we
present an update on the ﬁrst 64 pts (median of 48 [range: 24-86]
months) and report data on 18 additional pts transplanted between
February 2004 and January 2006. The 82 pts were given nonabla-
tive HCT from related (n52) or unrelated donors (n30). Me-
dian pt age was 55.5 (range 42-72) years, and the median number
of prior regimens was 4 (range 1-12). Seventy-nine pts were re-
fractory to at least 1 regimen, 72 to ﬂudarabine (FLU), 27 to
alkylating agents, 23 to rituxumab, 7 to CAMPATH®, and 3 had
failed high-dose autologous HCT. Thirty-six pts (44%) had dis-
ease responsive to the last chemotherapy [36% partial (PR) and 7%
complete remission (CR)] while 37 were resistant and 9 had un-
tested relapse. Conditioning for HCT consisted of 2 Gy TBI alone
(n13) or combined with FLU (n69), 90 mg/m2. All pts received
G-PBMC. The incidences of grades II, III, and IV acute GVHD
were 40%, 16%, and 2% respectively, and chronic extensive
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